Repetitive transcranial magnetic stimulation, or rTMS, was FDA approved in 2008 as a safe and effective noninvasive treatment for severe depression resistant to antidepressant medications. A small ...

Newswise — Yale School of Medicine (YSM) researchers have tested a new and potentially more sensitive neuroimaging tool for diagnosing behavioral variant frontotemporal dementia (bvFTD). They reported ...

In a recent review published by Molecular Psychiatry, researchers reviewed existing data on the contribution of neuroimaging modalities such as magnetic resonance imaging (MRI) and positron emission ...

Neuroimaging has become an indispensable tool in elucidating the pathophysiology of Parkinson’s disease, offering insight into both structural and functional alterations that underlie motor and ...

Imagine the ability to monitor brain activity at the molecular level in real-time! The possible scientific and medical applications are endless. Recent advancements in neuroscience have achieved this ...

Epilepsy surgery aims to resect or ablate epileptogenic tissue in patients with drug-resistant focal epilepsy. Surgical approaches have evolved from open resections to minimally invasive techniques ...

Newswise — STONY BROOK, N.Y., October 10, 2012 – Researchers from the Department of Biomedical Engineering at Stony Brook University have developed a high-resolution, 3D optical Doppler imaging ...

However, in nearly half of all cases, bvFTD is initially misdiagnosed, mistaken for conditions such as bipolar disorder or atypical depression. The neuroimaging technique fluorodeoxyglucose positron ...

Despite increased use of repetitive transcranial magnetic stimulation in psychiatry, the rates at which patients respond to the therapy and experience remission of often-disabling symptoms have been ...

TAMPA, Fla. (May 4, 2021) -- Repetitive transcranial magnetic stimulation, or rTMS, was FDA approved in 2008 as a safe and effective noninvasive treatment for severe depression resistant to ...

A newer technique, developed at Yale, uses PET imaging to detect a protein known as synaptic vesicle glycoprotein 2A (SV2A), which is found throughout the brain near synapses, where brain cells meet ...